Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
about
CpG Oligonucleotides as Cancer Vaccine AdjuvantsAntibody-based immunotherapy of solid cancers: progress and possibilitiesTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsThe role of regulatory T cells in cancer immunologyIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsNeoadjuvant anti-tumor vaccination prior to surgery enhances survival.Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008Targeting the tumor microenvironment to enhance antitumor immune responsesAd-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following ChemotherapyImmunomediated Pan-cancer Regulation Networks are Dominant Fingerprints After Treatment of Cell Lines with Demethylation.Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinomaA Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed GlioblastomaPD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer.Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation.Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells.Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune PathwaysRole of tumor microenvironment in tumorigenesis.Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy.The immunobiology of myeloid-derived suppressor cells in cancer.MOLECULAR PATHWAYS: TARGETING THE MICROENVIRONMENT OF LIVER METASTASES.Small cell lung cancer: Recruitment of macrophages by circulating tumor cells.Immune checkpoints and their inhibition in cancer and infectious diseases.Frequent expression of PD-L1 on circulating breast cancer cells.Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.Integrating liquid biopsies into the management of cancer.Immunomodulatory Nanomedicine.Dendritic Cell Therapies for Hematologic Malignancies.Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells.PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+ cancer cells.Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases.Tumor immune microenvironment characterization and response to anti-PD-1 therapy.Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.An Endogenous Vaccine Based on Fluorophores and Multivalent Immunoadjuvants Regulates Tumor Micro-Environment for Synergistic Photothermal and Immunotherapy.Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.A bifunctional nanomodulator for boosting CpG-mediated cancer immunotherapy.Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer.Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model.Liquid Biopsy in Head and Neck Cancer: Promises and Challenges.Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer.
P2860
Q26783826-65344BB3-60B1-4A82-B400-8CEF5F01014EQ26796542-D664BCC7-DF02-4E71-AFB9-02CE535AD8A8Q26996518-8CA990B6-9E13-4F99-93FF-99FC6319E462Q27006663-192D8DBA-4290-420B-A8A7-A60B0D5A6ED5Q28072532-D543C1C9-E1B3-4CA3-9984-51FB6752679AQ34145877-A3A50360-83B3-43F2-A7DE-D77849180F3BQ34306503-410566A3-88FE-45BB-A642-27F21E747BE9Q35176307-66AEFFEC-6DC1-459B-BA9A-4EB08F453D53Q35216973-EEF317F4-8123-4511-867D-305027F98EBAQ36848243-EAB3FC43-9A32-4FCD-843A-B92AFB2D1918Q37222152-8AFC2331-5152-4D5F-888D-B43D12F7F034Q37262109-7C2D8150-151F-4B5D-ACD8-44C13D9EDC31Q37352695-66AAF10E-86E7-41CD-B259-E598719CDF43Q37615676-8B424E61-6DDC-4666-ABE7-D8B4358855BEQ37641651-1C310EC4-8B01-418F-8249-8FB67CC343A2Q37690959-EF032ABD-B1DF-42EF-8AF9-6550188EDFA6Q37738074-8E53997E-D7FB-4839-AAED-B9278A2EBC05Q38548889-EB05151F-E404-4AB8-B00B-5997A45F7384Q38649547-7FAA6EED-AA40-4943-B65A-A87B61985F7CQ38671001-E170A7FB-BAA2-48E3-822B-0CC625C4301CQ38773484-15D5E4B9-03C3-4897-BDE8-4D6CDA5A531DQ38845026-630AA436-BB84-46D5-94A1-5A7AD86895DDQ38861829-2403154D-91ED-4612-8514-12177B5E525CQ38878888-C6E1C312-B86A-4A60-A3A8-09C6FABC56C6Q39157824-474B83E6-9870-4D3D-B04F-D0212BB57296Q39224331-E629477A-B2DF-4DE1-946B-BF4B5DA541C9Q39289930-E85271B9-C94F-419B-9606-B9654EEF49BEQ40253347-B28D17E6-2565-4B30-8D93-D5CC04C60067Q40309584-CD78FB57-DAE8-49B9-B91E-5C0424C6A8D7Q41057575-BE04B20E-DCF6-448F-B54F-B211A2D0E5DBQ41265675-AF754318-3EB6-48AD-AEA2-7BE0D08287CFQ41336719-D09AF128-0F25-49CF-950D-6CB61C281F15Q48508291-38058C1C-F900-43B7-92B9-2264B0E3EEF6Q48533171-18417513-9B85-45C6-8EBA-9A610461768AQ49434203-1493CF24-8A68-4284-A8FA-AFBBC0E73930Q50072990-A14F25B6-B1D8-4847-B783-5E0042E76FE7Q51034587-EA43F274-D5E4-4362-80D9-F0C4FE03A461Q51453480-CB082BF8-27CD-4898-B7BF-DECFD549C7CFQ52669514-3E82DF19-E571-4D18-BD59-A744A198AFD4Q53079766-7693C92D-4A3D-4A97-BFDB-3CB8A54E3CEC
P2860
Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immunosuppressive networks and ...... munotherapeutics and vaccines.
@en
type
label
Immunosuppressive networks and ...... munotherapeutics and vaccines.
@en
prefLabel
Immunosuppressive networks and ...... munotherapeutics and vaccines.
@en
P2860
P356
P1433
P1476
Immunosuppressive networks and ...... mmunotherapeutics and vaccines
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2013.432
P407
P577
2013-10-21T00:00:00Z
P6179
1003134495